SCHEMBL16748418

SCHEMBL16748418

Nc1nc(Nc2ccc(Cl)cc2)nc(-n2c(C3CC3)nc3cc(F)ccc32)n1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BMI1 P35226 4/20 0.42
DHFR P00374 4/20 0.38
TBXA2R P21731 3/20 0.38
AGPAT2 O15120 2/20 0.38
ALDH1A1 P00352 2/20 0.38
BLM P54132 2/20 0.36
KDM4E B2RXH2 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
SLC6A2 P23975 1/20 0.36
PDE4A P27815 1/20 0.36
KDR P35968 1/20 0.36
MAPT P10636 2/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
EGFR P00533 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16740849 0.92 BMI1 (0.51) BMI1DHFRAGPAT2ALDH1A1BLM
SCHEMBL16748448 0.90 BMI1 (0.42) BMI1DHFRAGPAT2ALDH1A1BLM
SCHEMBL16748423 0.90 CYBB (0.43) BMI1DHFRALDH1A1BLMKDM4E
SCHEMBL16748493 0.89 BMI1 (0.56) BMI1DHFRALDH1A1BLMKDM4E
SCHEMBL16748422 0.88 BMI1 (0.49) BMI1DHFRALDH1A1KDM4ESMN1; SMN2
SCHEMBL16748497 0.86 BMI1 (0.51) BMI1ALDH1A1MAPT
SCHEMBL16740742 0.86 BMI1 (0.47) BMI1ALDH1A1KDM4EADORA3SLC6A2
SCHEMBL16740843 0.82 BMI1 (0.51) BMI1DHFRALDH1A1BLMKDM4E
SCHEMBL16748514 0.82 BMI1 (0.40) BMI1DHFRALDH1A1
SCHEMBL16740786 0.81 DHFR (0.44) BMI1DHFRTBXA2RAGPAT2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B BMI1 1/4885DHFR 4017/4885TBXA2R 4287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.